Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from MiNK Therapeutics ( (INKT) ).
On September 23, 2025, MiNK Therapeutics elected Dr. John Holcomb as a Class II director, with his term expiring in 2026. Dr. Holcomb, a renowned expert in trauma and critical care, joins MiNK to enhance its leadership as it advances iNKT therapies for immune-mediated diseases and global health security. His appointment underscores MiNK’s commitment to addressing significant health challenges and expanding its therapeutic pipeline.
The most recent analyst rating on (INKT) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on MiNK Therapeutics stock, see the INKT Stock Forecast page.
Spark’s Take on INKT Stock
According to Spark, TipRanks’ AI Analyst, INKT is a Underperform.
MiNK Therapeutics’ overall stock score reflects significant financial challenges and negative market sentiment. The company’s ongoing losses, reliance on external financing, and technical indicators pointing to potential downward momentum weigh heavily on the score. Despite promising clinical advancements and strategic partnerships, financial instability and valuation challenges remain primary concerns.
To see Spark’s full report on INKT stock, click here.
More about MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. Their platform aims to restore immune balance and drive cytotoxic immune responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK’s lead asset, AGENT-797, is in clinical development for treating graft-versus-host disease, solid tumors, and critical pulmonary immune collapse.
Average Trading Volume: 1,004,364
Technical Sentiment Signal: Strong Buy
Current Market Cap: $63.14M
For a thorough assessment of INKT stock, go to TipRanks’ Stock Analysis page.